VRNA vs. FGEN, IRWD, XNCR, DICE, RCKT, AUPH, ZNTL, AMLX, BLU, and GERN
Should you be buying Verona Pharma stock or one of its competitors? The main competitors of Verona Pharma include FibroGen (FGEN), Ironwood Pharmaceuticals (IRWD), Xencor (XNCR), DICE Therapeutics (DICE), Rocket Pharmaceuticals (RCKT), Aurinia Pharmaceuticals (AUPH), Zentalis Pharmaceuticals (ZNTL), Amylyx Pharmaceuticals (AMLX), BELLUS Health (BLU), and Geron (GERN). These companies are all part of the "pharmaceutical preparations" industry.
Verona Pharma vs.
Verona Pharma (NASDAQ:VRNA) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, community ranking, media sentiment, analyst recommendations, dividends and profitability.
76.9% of FibroGen shares are owned by institutional investors. 3.9% of Verona Pharma shares are owned by insiders. Comparatively, 2.8% of FibroGen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, FibroGen had 1 more articles in the media than Verona Pharma. MarketBeat recorded 4 mentions for FibroGen and 3 mentions for Verona Pharma. Verona Pharma's average media sentiment score of 0.93 beat FibroGen's score of 0.22 indicating that Verona Pharma is being referred to more favorably in the media.
Verona Pharma has a net margin of 0.00% compared to FibroGen's net margin of -264.63%. Verona Pharma's return on equity of -28.33% beat FibroGen's return on equity.
Verona Pharma has higher earnings, but lower revenue than FibroGen. Verona Pharma is trading at a lower price-to-earnings ratio than FibroGen, indicating that it is currently the more affordable of the two stocks.
Verona Pharma has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.
FibroGen received 44 more outperform votes than Verona Pharma when rated by MarketBeat users. However, 79.68% of users gave Verona Pharma an outperform vote while only 63.69% of users gave FibroGen an outperform vote.
Verona Pharma currently has a consensus price target of $29.33, indicating a potential upside of 37.14%. FibroGen has a consensus price target of $23.40, indicating a potential upside of 40.12%. Given FibroGen's higher possible upside, analysts clearly believe FibroGen is more favorable than Verona Pharma.
Summary
Verona Pharma beats FibroGen on 11 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Verona Pharma Competitors List
Related Companies and Tools